BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma

Inhibitors of RAF inhibit the MAPK pathway that plays an important role in the development and progression of those melanoma carrying the V600E BRAF mutation, but there’s a subset of such patients who do not respond to the therapy. Various mechanisms of drug resistance have been proposed which inclu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Appl Immunohistochem Mol Morphol
Egile Nagusiak: Chiappetta, Caterina, Proietti, Ilaria, Soccodato, Valentina, Puggioni, Chiara, Zaralli, Roberto, Pacini, Luca, Porta, Natale, Skroza, Nevena, Petrozza, Vincenzo, Potenza, Concetta, Della Rocca, Carlo, Di Cristofano, Claudio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2015
Gaiak:
Review Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482453/
https://ncbi.nlm.nih.gov/pubmed/24710085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PAI.0000000000000071
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak